---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-006973"
form_type: "8-K"
ticker: "CRVS"
cik: "0001626971"
company_name: "Corvus Pharmaceuticals, Inc."
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:38:27.682995+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Corvus Pharms Q3 net loss $10.2M, cash $65.7M; soquelitinib trials advancing

## Summary
- Net loss of $10.2M for Q3 2025, improved from $40.2M loss in Q3 2024 which included $32.8M non-cash warrant liability loss.
- Cash, equivalents & marketable securities $65.7M as of Sept 30, 2025, up from $52.0M at Dec 31, 2024; funding expected into Q4 2026.
- Completed enrollment in soquelitinib atopic dermatitis Phase 1 extension cohort 4 (200 mg BID, 8 weeks); data expected January 2026.
- On track to initiate soquelitinib atopic dermatitis Phase 2 trial in early Q1 2026, targeting ~200 patients.
- Phase 3 registrational trial of soquelitinib in relapsed/refractory PTCL enrolling; final Phase 1/1b results to be presented at ASH December 2025.

## SEC filing metadata
- accession: 0001171843-25-006973
- form_type: 8-K
- ticker: CRVS
- cik: 0001626971
- company_name: Corvus Pharmaceuticals, Inc.
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1626971/000117184325006973/0001171843-25-006973-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1626971/000117184325006973/f8k_110425.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-006973
- JSON: https://secwatch.observer/filing/0001171843-25-006973.json
- Plain text: https://secwatch.observer/filing/0001171843-25-006973.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.